Public Employees Retirement System of Ohio boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 10.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,823 shares of the biotechnology company’s stock after buying an additional 1,898 shares during the period. Public Employees Retirement System of Ohio’s holdings in United Therapeutics were worth $2,440,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Legal & General Group Plc raised its holdings in shares of United Therapeutics by 13.5% in the second quarter. Legal & General Group Plc now owns 81,297 shares of the biotechnology company’s stock valued at $10,547,000 after purchasing an additional 9,664 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of United Therapeutics by 2.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock valued at $15,959,000 after purchasing an additional 2,762 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of United Therapeutics by 20.9% in the second quarter. Victory Capital Management Inc. now owns 6,549 shares of the biotechnology company’s stock valued at $850,000 after purchasing an additional 1,133 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of United Therapeutics by 18.9% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 12,764 shares of the biotechnology company’s stock valued at $1,656,000 after purchasing an additional 2,025 shares during the last quarter. Finally, Utah Retirement Systems raised its holdings in shares of United Therapeutics by 1.2% in the second quarter. Utah Retirement Systems now owns 8,165 shares of the biotechnology company’s stock valued at $1,060,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 99.99% of the company’s stock.

In other news, CEO Martine A. Rothblatt sold 7,061 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $121.12, for a total value of $855,228.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total transaction of $78,137.60. Following the completion of the transaction, the director now owns 1,555 shares of the company’s stock, valued at $209,489.60. The disclosure for this sale can be found here. Insiders have sold 18,872 shares of company stock valued at $2,302,672 in the last 90 days. 7.80% of the stock is currently owned by corporate insiders.

Several analysts have recently commented on the stock. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. HC Wainwright reiterated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Wedbush reiterated an “outperform” rating and issued a $232.00 target price (up previously from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. ValuEngine upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Finally, Cowen reiterated a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a report on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $138.00.

Shares of United Therapeutics Co. (UTHR) opened at $147.95 on Monday. United Therapeutics Co. has a 1-year low of $112.01 and a 1-year high of $169.89. The stock has a market cap of $6,393.07, a PE ratio of 13.05 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The business had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. During the same quarter last year, the company posted $4.23 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. analysts forecast that United Therapeutics Co. will post 12.96 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-grows-holdings-in-united-therapeutics-co-uthr/1790319.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.